PolyPid (PYPD): Analyst Targets Suggest a Path to $11 and +67% Upside

Key Takeaways

• The $11 central target reflects the arithmetic mean of four current analyst price targets for PolyPid, which average roughly $10.75.
• At a recent price near $6.60, reaching $11 would require an advance of about 67%.
• The four targets range from $8 to $13, indicating notable dispersion in views on fair value.
• Key supports include the November 28, 2026 PDUFA goal date for D-PLEX100 and the Azurity commercialization agreement.
• Major risks center on FDA approval uncertainty, hospital-by-hospital launch execution, and the company’s pre-revenue, cash-burning status.
• Readers can track Major News, Today's Price Move, the Forecast, and Earnings for updates on PolyPid.

Analyst Price Targets and Consensus View

PolyPid Ltd. (PYPD) is a clinical-stage biopharmaceutical company based in Petah Tikva, Israel. Its lead candidate, D-PLEX100, is designed to prevent surgical site infections in patients undergoing abdominal colorectal surgery.

Coverage remains limited but generally positive. The four attributable targets I reviewed include H.C. Wainwright’s reiterated Buy rating with a $13 target from late October 2026, Oppenheimer’s Outperform initiation with a $10 target on October 27, 2026, Craig-Hallum’s maintained Buy and $12 target from July 2026, and Roth MKM’s reiterated Buy with an $8 target from August 2026. The arithmetic mean of $13, $12, $10, and $8 comes to roughly $10.75, which rounds neatly to the $11 central target. The $8-to-$13 spread is wide, reflecting real differences in how quickly analysts expect D-PLEX100 to reach approval and commercialization. No sell-rated targets appeared in the current set, though the small sample size means the consensus should be viewed cautiously.

Current Market Position and Path Toward the Target

As of the most recent close, PYPD traded near $6.60, corresponding to a market capitalization of roughly $134 million. Achieving the $11 target would require an advance of about 67%, a sizable move that would likely depend on positive clinical and regulatory developments rather than steady multiple expansion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The near-term outlook is highly binary. The FDA accepted the company’s NDA for D-PLEX100 and granted Priority Review, setting a PDUFA goal date of November 28, 2026. Management expects a potential U.S. launch in early 2027 if approved. Because PolyPid is pre-revenue, valuation rests almost entirely on expectations for that decision and the subsequent launch trajectory.

What Could Support a Move Toward the Target

• D-PLEX100 achieved its primary and key secondary endpoints in the Phase 3 SHIELD II trial, supporting a favorable regulatory review.
• The Azurity Pharmaceuticals partnership brings $30 million in upfront and near-term milestone payments, eligibility for more than $290 million in additional milestones, and tiered royalties in the mid-teens to mid-20s on U.S. and Canadian sales.
• PolyPid has indicated that its cash position, together with expected Azurity proceeds, should fund operations into 2028.
• An EMA application was validated in September 2026, with a potential decision in the second half of 2027.
• An Azurity-funded label-expansion program could extend D-PLEX100 into additional surgical indications.

What Could Prevent the Target From Being Reached

• FDA approval is not assured; a Complete Response Letter or delay would likely pressure the shares sharply.
• The commercial launch is expected to proceed hospital by hospital, and adoption, formulary access, and reimbursement remain unproven.
• The company is pre-revenue, posted a third-quarter 2026 net loss of about $5.8 million, and may need additional capital later despite the extended runway.
• With roughly 20 million shares outstanding plus warrants, future dilution could affect per-share value.
• The wide $8-to-$13 target range illustrates how much value even bullish analysts assign to an unapproved product.

Technical Levels and Market Structure

The stock’s 52-week range spans roughly $3.50 to $7.15. Shares reached the upper end of that range in November 2026, making the $7.15 area a meaningful resistance level. The $5.50-to-$5.90 zone served as a consolidation area during October 2026, while the round-number $5.00 level may act as psychological support. A decisive move through $7.15 would mark a notable technical development on any path toward the higher target, whereas a failure to hold above $6.00 could indicate fading momentum.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a 12-month research horizon, though the underlying reports use varying assumptions. The most important near-term catalyst remains the November 28, 2026 PDUFA decision for D-PLEX100, followed by any FDA manufacturing inspection outcomes, the early-2027 launch ramp, Azurity milestone payments, and progress on the EMA review. Investors should also watch for label-expansion updates, the CMS New Technology Add-on Payment decision expected in 2027, and any capital-raising activity.

Exploring AI Daily Buy/Sell Signals for Event-Driven Names

In my own workflow, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor how market conditions and technical behavior shift for volatile, catalyst-driven stocks like PolyPid. The tool applies artificial intelligence to thousands of equities and ETFs, producing Buy, Sell, or Hold signals that can complement manual chart review. For names where a single regulatory event can move the price sharply, this type of systematic view helps keep track of changing trends without replacing individual judgment.

Final Assessment

The $11 central target is the rounded average of four current analyst price targets ranging from $8 to $13 and sits roughly 67% above the recent price near $6.60. Reaching it would require a substantial advance driven primarily by a favorable FDA decision on D-PLEX100 and credible commercial execution. The Azurity deal, extended cash runway, and validated European application provide meaningful support, yet approval risk, slow hospital adoption, and a pre-revenue balance sheet remain substantial hurdles. The unusually wide analyst range underscores how much hinges on a single regulatory event, making the near-term outcome more about catalysts than steady fundamentals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume